05/03/10
Data Presented by Ocera Therapeutics at DDW Demonstrates that Neurocognitive Impairment is Highly Prevalent in Ambulatory Cirrhotic Patients
05/03/10
Ocera Therapeutics Demonstrates Proof of Principle for the Use of AST-120 in the Treatment of Non-Constipating Irritable Bowel Syndrome
04/16/10
Ocera Therapeutics Presents Data on the Prevalence of Mild Hepatic Encephalopathy Defined as Neurocognitive Impairment in Patients with Liver Cirrhosis at EASL Annual Meeting